Actively Recruiting
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Led by University of California, San Diego · Updated on 2026-03-05
48
Participants Needed
1
Research Sites
362 weeks
Total Duration
On this page
Sponsors
U
University of California, San Diego
Lead Sponsor
T
The Institute for Follicular Lymphoma Innovation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lymphomas. The main questions this clinical trial aims to answer are: What is the maximum dose of SB-4826 that can be used safely in patients with solid tumors and non-Hodgkin lymphomas, and will it work? How does SB-4826 work in people with cancer? How is SB-4826 absorbed, broken down, and excreted by the body? Participants will: Take drug SB-4826 twice weekly for up to 1 year; keep a diary of when they take SB-4826 at home; visit the clinic for checkups, tests, and fill out study questionnaires.
CONDITIONS
Official Title
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 and older.
- Able to give signed informed consent.
- Phase 1: Diagnosed with locally advanced or metastatic solid tumor (excluding brain/CNS tumors) or non-Hodgkin lymphoma with need for systemic therapy.
- Phase 2: Diagnosed with non-Hodgkin lymphoma planned to receive rituximab.
- Cancer has relapsed, progressed, or patient is not a candidate for or refuses standard therapies.
- For solid tumors, at least one measurable lesion per RECIST v1.1.
- Adequate blood counts unless affected by cancer.
- Adequate organ function with specified kidney and liver enzyme levels.
- Prior therapy side effects resolved to grade 2 or less (except hair loss).
- Life expectancy of at least 3 months.
- Performance status of 2 or less.
- Female participants must not be pregnant or breastfeeding and follow specified contraception requirements.
- Male participants must agree to contraception or abstinence requirements during and after the study.
You will not qualify if you...
- Unable to take oral medications.
- Use of systemic cancer therapy within 21 days or 5 half-lives, whichever is shorter.
- Palliative radiation within 7 days before study drug.
- Cellular therapy within 60 days before study drug.
- Major surgery within 30 days before study drug.
- Prior solid organ transplant.
- Significant cardiovascular disease within 6 months before study drug.
- Other malignancies within 2 years except certain treated cancers.
- Chronic liver diseases considered clinically significant.
- Prolonged QT interval >470 msec.
- Active infection requiring treatment within 14 days.
- Active hepatitis B or C infection.
- HIV with viral load >50 copies/ml at screening.
- Active autoimmune disease needing high-dose steroids or immunosuppressants.
- Use of certain medications affecting drug metabolism within 14 days.
- Receipt of live vaccines within 30 days before study drug.
- Receipt of investigational products within 21 days or 5 half-lives.
- History of severe immune-related adverse events from prior immunotherapy.
- Active central nervous system metastases (stable treated brain metastases allowed).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Diego
La Jolla, California, United States, 92093
Actively Recruiting
Research Team
P
Peter Vu, MD
CONTACT
E
Experimental Therapeutics Research Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here